Clinical trial NCT01554657: Five Versus Seven Day Antibiotic Course for the Treatment of Pneumonia in the Intensive Care Unit
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pneumonia, Bacterial
Keywords: Pneumonia, Bacterial
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
First posted: 2012-03-15
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of the study is to determine if patients who are being treated for pneumonia in the intensive care unit can be safely treated with five days of antibiotics (the current standard is seven to eight days). The goal is to determine if the investigators can minimize antibiotic complications while still treating the infection. Patients in the study are randomly assigned to either receive antibiotics for a goal of five days or a goal of seven days. Every patient is followed daily, and if they are not responding to the antibiotics, the treating team in the intensive care unit care can continue the antibiotics for a longer course regardless of what group the patient is assigned. The investigator's hypothesis is that patients in the five day treatment goal will be able to receive less antibiotics than patients in the seven day treatment goal without any adverse effects.

Detailed description: This is a pilot study to determine if patients with pneumonia in the intensive care unit can safely receive five days of antibiotics. All patients admitted to the medical and surgical intensive care units at Barnes-Jewish Hospital with pneumonia will be screened for the inclusion and exclusion criteria. Patients will be randomized by sealed envelopes in groups of six to a five or seven day course of antibiotics. The choice of the antibiotic to be used is determined by the intensive care unit treating team. The patients will NOT be randomized to a specific antibiotic. The patients will be followed for a clinical response by improvement in maximum daily temperature, white blood cell count, and PaO2 to FiO2 ratio. Antibiotics can continue past the goal duration for patients in either group if the above criteria are not met or if the attending physician in the intensive care unit feels that a longer course is needed. The treating team in the intensive care unit will not be blinded to the patient's treatment assignment.

Eligibility criteria: Inclusion Criteria:

* New diagnosis of pneumonia
* Patient in medical or surgical intensive care unit
* Age greater or equal than 18 years old

Exclusion Criteria:

* Neutropenia
* Recipient of a solid organ or bone marrow transplant
* Bacteremia
* Presence of Acinetobacter baumannii or Stenotrophomonas maltophilia from a respiratory tract culture
* Presence of a second infection requiring antibiotic therapy
* Pregnancy
* Enrollment in another clinical study
* Patient or surrogate unable to provide informed consent
* Attending intensive care unit physician declined enrollment in the study

Primary outcomes:
measure: Length of antibiotic therapy
timeFrame: 28 days
Secondary outcomes:
measure: Mortality
timeFrame: 28 days
measure: Hospital Length of Stay
timeFrame: 28 Days
measure: Clostridium difficile diarrhea
timeFrame: 28 Days
measure: Development of a new multi-drug resistant bacteria from a lower respiratory tract culture
timeFrame: 28 days
measure: Recurrent lower respiratory tract infection
timeFrame: 28 days
Other outcomes:
Locations:
Study officials:
References: